Who is sponsoring NCT00956722?

NCT00956722 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT00956722?

Interventions in NCT00956722: Bovine Colostrum Powder.

What condition does NCT00956722 study?

NCT00956722 studies Asymptomatic Chronic HCV Carriers.

Is NCT00956722 still recruiting?

NCT00956722 is currently withdrawn. Last updated 27 August 2012.

Last reviewed 2012-08-27 · How we verify

NCT00956722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy

Withdrawn Phase 1 Last updated 27 August 2012

What this trial tests

Phase 1 trial testing Bovine Colostrum Powder in Asymptomatic Chronic HCV Carriers. Withdrawn.

Timeline

1 January 2012

Primary endpoint
1 January 2014

1 April 2014

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 January 2012
Primary completion	1 January 2014
Estimated completion	1 April 2014
Sites	1 location across Israel

Drugs / interventions tested

Bovine Colostrum Powder — full drug profile →

Conditions studied

Asymptomatic Chronic HCV Carriers — all drugs for Asymptomatic Chronic HCV Carriers →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

18 and older, any sex, with Asymptomatic Chronic HCV Carriers. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To determine if the administration of BCP will reduce the levels of intestinal microbial products in the bloodstream of HCV-infected, untreated persons.
Time frame: 10 weeks
To determine the safety of the administration of oral BCP to patients with chronic HCV
Time frame: 12 weeks

Sponsor's own description

This is an exploratory trial of Bovine Colostrum powder to decrease translocation of gut-derived microbial products and immune activation in HCV infection. The study is designed as a single-arm, open-label, before-and after exploratory trial of 10 weeks of Bovine Colostrum Powder (BCP) to reduce translocation of intestinal microbial products and immune activation in patients suffering from chronic hepatitis C virus (HCV) infection. The study population will include HCV-infected (genotype 1) men and women, ≥ 18 years of age, not receiving anti-viral therapy at the time of enrollment and for at least the previous 3 months. Having failed previous anti-viral therapy (non responders), HCV recurrence after 72 weeks of therapy, developed side effects which mandated stopping anti viral therapy, or not considered eligible for initiation of such treatment, with a plasma HCV RNA level ≥ 1000 I.U.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00956722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 27 August 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00956722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing